Back to Search Start Over

Recurrence or reactivation of SARS-CoV-2 infection after immunosuppressive therapy in patients with ANCA-associated vasculitis and COVID-19.

Authors :
Mbengue M
Bigirimana B
Irankunda LR
Dial MC
Niang A
Source :
Clinical nephrology. Case studies [Clin Nephrol Case Stud] 2022 Jan 05; Vol. 10, pp. 6-10. Date of Electronic Publication: 2022 Jan 05 (Print Publication: 2022).
Publication Year :
2022

Abstract

. Acute tubular injury is the lesion most frequently described in this disease. However, four cases of ANCA-associated vasculitis (AAV) with COVID-19 with pauci-immune glomerulonephritis have recently been described. We report the case of an African woman, aged 70, in whom we diagnosed an AAV with pauci-immune glomerulonephritis in the context of COVID-19. She was treated with hydroxychloroquine and azithromycin for COVID-19. Corticosteroids and cyclophosphamide have been used for the treatment of vasculitis. The evolution was marked by the reappearance of COVID-19 one month after the beginning of an immunosuppressive therapy. The patient died a week later from respiratory failure. The occurrence of AAV during COVID-19 may not be due an unfortunate association but triggered by infection with SARS-CoV-2. The use of immunosuppressive therapy should be discussed due to the potential risk of reactivation or recurrence of the viral infection.<br /> (© Dustri-Verlag Dr. K. Feistle.)

Details

Language :
English
ISSN :
2196-5293
Volume :
10
Database :
MEDLINE
Journal :
Clinical nephrology. Case studies
Publication Type :
Report
Accession number :
35028280
Full Text :
https://doi.org/10.5414/CNCS110567